LDL and HDL subclass distribution in patients with end-stage renal diseases

Alabakovska, S.; Todorova, B.; Labudovic, Danica; Tosheska, Katerina

doi:10.1016/s0009-9120(02)00300-4

Cited by 31 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDL 2 particles are mostly involved in removal of cholesterol from foam cells, as potent acceptors of excess cellular cholesterol [44]. In our study we found a significant reduction in the serum levels of total HDL and especially HDL 2 -C as compared with the normal population.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Effect of <i>L</i>-Carnitine on the Serum Lipoproteins and HDL-C Subclasses in Hemodialysis Patients

Argani

Rahbaninoubar²,

Ghorbanihagjo³

et al. 2005

Nephron Clin Pract

View full text Add to dashboard Cite

Aims: Following carnitine administration a decrease in plasma levels of triglyceride (TG) and increase in total high-density lipoprotein cholesterol (HDL-C) has been reported. Our hypothesis was that it also improves the HDL₂/HDL₃ ratio, symptomatic intradialytic hypotension, and anemia in hemodialysis (HD) patients. Methods: Forty HD patients with a mean (± SD) age of 53 ± 13 years were treated with 500 mg/day carnitine taken orally for 2 months. Patients were used as their own controls (before treatment). Lipid and lipoproteins were determined by Alcyon Abbott autoanalyzer. HDL subclasses were measured by magnesium precipitation after fractionation with dextran sulfate. Hemoglobin, hematocrit and serum albumin were measured by standard methods. The results were analyzed by SPSS 11.05. Results: We found a significant decrease in serum TG (2.22 ± 0.99 vs. 1.93 ± 1.07 mmol/l, p < 0.01) and VLDL-C (0.93 ± 0.36 vs. 0.81 ± 0.34 mmol/l, p = 0.01) and a marked increase in HDL-C (0.9 ± 0.16 vs. 1.06 ± 0.24 mmol/l, p < 0.05), HDL₂-C (0.17 ± 0.06 vs. 0.27 ± 0.14 mmol/l, p < 0.05) and albumin (37 ± 4 vs. 42 ± 5 g/l, p = 0.01) levels. The serum levels of total cholesterol (4.61 ± 0.89 vs. 4.5 ± 0.95 mmol/l, p = 0.1), LDL-C (2.78 ± 0.85 vs. 2.6 ± 0.89 mmol/l, p > 0.05), HDL₃-C (0.73 ± 0.1 vs. 0.79 ± 0.17 mmol/l, p > 0.05), hemoglobin, hematocrit, and intradialytic blood pressure did not change after the treatment. Conclusion: Treatment with 500 mg/day carnitine taken orally for 2 months reduces serum levels of TG and VLDL-C, and increases HDL-C, HDL₂-C and albumin in HD patients.

show abstract

Section: Discussionsupporting

confidence: 58%

“…Although LCAT activity is reduced in HD patients, some authors have found that dialysis itself normalizes LCAT activity [20]. On the basis of ultracentrifugation, decreased HDL 2 and increased HDL 3 levels have been reported in patients with renal failure [21, 22]. …”

Section: Introductionmentioning

confidence: 99%

Effect of <i>L</i>-Carnitine on the Serum Lipoproteins and HDL-C Subclasses in Hemodialysis Patients

Argani

Rahbaninoubar²,

Ghorbanihagjo³

et al. 2005

Nephron Clin Pract

View full text Add to dashboard Cite

show abstract

“…As known, HDL3-C subclass constitutes a large proportion of antioxidant enzymes within HDL, including PON1, whereas HDL2-C is mostly involved in removal of cholesterol in patients with end-stage renal disease. 7,25 The higher HDL3-C subclass levels which were shown to be related to higher PON1 activity, 4,7 may possibly explain the marginally increased PON1 concentration observed in patients treated with statins of the present study. Linear regression analysis verified the strong associations between PON1 HDL-C and HDL3-C concentrations in RF and HD groups.…”

Section: Discussionmentioning

confidence: 63%

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are at high risk of atherosclerotic events; dyslipoproteinemia and the decrease of the HDL-linked enzyme paraoxonase 1 (PON1), might have a major role. This study intends to compare the association between lipid profile and serum PON1 levels in renal failure (RF) and hemodialysis (HD) patients. Serum lipids, HDL-subclasses and PON1 concentration were evaluated in 90 patients with CKD, divided into groups: RF (n ¼ 46) and HD (n ¼ 44), and in 30 normal individuals (control group). The results showed that PON1 was significantly lower in HD patients than in RF and controls (p50.001). In RF patients under statin therapy, PON1 did not differ from that of patients without statins. In HD patients without statins, PON1 was considerably low, whereas in HD with statins (30.42 ± 12.62 mg/mL) was lower than RF with statins (49.31 ± 14.94, p50.001). PON1 concentration was significantly and positively associated with HDL-C, HDL3-C and Apo A1 in all groups. Additionally, in HD patients PON1 was negatively associated with LDL-C. Multiple regression analysis revealed that LDL-C and statin treatment were independently related to PON1 concentration in HD patients (b ¼ À0.331, p ¼ 0.026 and b ¼ 0.344, p ¼ 0.020, respectively). In RF patients, HDL3-C and Apo A1 are strong determinants of PON1 levels. It is concluded that different parameters of lipid profile seem to affect serum PON1 concentration of RF and HD patients and probably contribute to the delay of atherosclerosis.ARTICLE HISTORY

show abstract

“…We observed that the concentration of HDL3-C and not of HDL2-C subclass is lower in HD and PD patients compared with NC, which is in agreement with the report of Schiavon et al referring to HD patients. 17 However, it contradicts with other studies where decreased levels of the largest HDL2b subclass and increased levels of small HDL3a subclass were separated from plasma of HD patients by polyacrylamide gradient gel electrophoresis 16 or decreased levels of both HDL2-C and HDL3-C were found. 19,20 The above discrepancies could be either the result of different procedures of HDL-C subclass isolation or due to statistical comparison of different number of sample groups.…”

Section: Discussionmentioning

confidence: 80%

“…14 There is limited evidence concerning the comparison of oxLDL concentration in patients treated with different modes of dialysis, 15 although there are few studies about the comparison of antibodies against oxLDL in dialysis subgroups of patients. Also to our knowledge, the effect of hemodialysis (HD) on distribution of HDL subclasses in serum has been studied recently [16][17][18][19][20] but no data about the effect of peritoneal dialysis (PD) have been reported. This study attempts to look into the comparison of oxLDL levels, lipids, and lipoproteins in patients on HD and PD and in normal controls (NC).…”

Section: Introductionmentioning

confidence: 99%

Lipid Abnormalities and Oxidized LDL in Chronic Kidney Disease Patients on Hemodialysis and Peritoneal Dialysis

et al. 2011

View full text Add to dashboard Cite

Dyslipoproteinemia and oxidative modification of low-density lipoprotein (oxLDL) contribute to the development of oxidative stress and atherosclerosis in chronic kidney disease (CKD). On the contrary, high-density lipoprotein cholesterol (HDL-C), especially HDL3-C subtype, has protective effect against oxidative damage. There is limited evidence referring HDL-C subclass levels in patients on dialysis. This study was designed to compare lipid abnormalities and oxLDL levels in hemodialysis (HD) and peritoneal dialysis (PD) patients. Serum lipids, HDL subclasses, and oxLDL were measured in 55 patients with CKD-stage 5 (31 patients on HD and 24 patients on PD) and in 21 normal controls (NC). The results showed that in dialysis patients, triglycerides were higher than in controls (p < 0.0001) and HDL-C was significantly lower (p < 0.0001). The HDL2-C subclass concentration did not differ significantly between patients and controls, while HDL3-C was lower in patients (11 ± 0.5 mg/dL) than in NC (23 ± 1, p < 0.0001). oxLDL levels were markedly increased in patients (1.92 ± 0.29 mg/L) compared to NC (0.22 ± 0.05, p < 0.0001). Patients on PD had higher levels of cholesterol (p < 0.001) and apolipoprotein B (p < 0.05) than patients on HD. However, HDL-C, HDL-C subclasses, and oxLDL concentrations did not differ significantly between PD and HD patients. It is concluded that patients with CKD have a nearly 10-fold elevation of oxLDL compared with NC. Patients on PD have differences in the lipid profile compared with patients on HD; however, both modalities seem to possess similar potential to atherosclerosis development.

show abstract

LDL and HDL subclass distribution in patients with end-stage renal diseases

Cited by 31 publications

References 22 publications

Effect of <i>L</i>-Carnitine on the Serum Lipoproteins and HDL-C Subclasses in Hemodialysis Patients

Effect of <i>L</i>-Carnitine on the Serum Lipoproteins and HDL-C Subclasses in Hemodialysis Patients

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Lipid Abnormalities and Oxidized LDL in Chronic Kidney Disease Patients on Hemodialysis and Peritoneal Dialysis

Contact Info

Product

Resources

About